MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of
Thrombotic Risk in Patients with Acute Myocardial Infarction
and Primary Angioplasty

J 2021

MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty

HROMADKA, Milan, Zuzana MOTOVSKA, Ota HLINOMAZ, Petr KALA, Frantisek TOUSEK et. al.

Basic information

Original name

MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty

Authors

HROMADKA, Milan (203 Czech Republic), Zuzana MOTOVSKA (203 Czech Republic), Ota HLINOMAZ (203 Czech Republic, belonging to the institution), Petr KALA (203 Czech Republic, belonging to the institution), Frantisek TOUSEK (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Markéta BERANOVÁ (203 Czech Republic, belonging to the institution), Pavel JANSKY (203 Czech Republic), Michal SVOBODA (203 Czech Republic, belonging to the institution), Iveta KŘEPELKOVÁ (203 Czech Republic), Richard ROKYTA (203 Czech Republic), Petr WIDIMSKY (203 Czech Republic) and Michal KARPISEK (203 Czech Republic)

Edition

JOURNAL OF PERSONALIZED MEDICINE, BASEL, MDPI, 2021, 2075-4426

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30218 General and internal medicine

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.508

RIV identification code

RIV/00216224:14110/21:00121971

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.3390/jpm11060508

UT WoS

000666506600001

Keywords in English

acute myocardial infarction; risk stratification; microRNA; miR-126-3P; miR-223-3p; antithrombotic therapy individualization

Abstract

V originále

Aim. This study was designed to evaluate the relationship between microRNAs (miRNAs), miR-126-3p and miR-223-3p, as new biomarkers of platelet activation, and predicting recurrent thrombotic events after acute myocardial infarction (AMI). Methods and Results. The analysis included 598 patients randomized in the PRAGUE-18 study (ticagrelor vs. prasugrel in AMI). The measurements of miRNAs were performed by using a novel miRNA immunoassay method. The association of miRNAs with the occurrence of the ischemic endpoint (EP) (cardiovascular death, nonfatal MI, or stroke) and bleeding were analyzed. The miR-223-3p level was significantly related to an increased risk of occurrence of the ischemic EP within 30 days (odds ratio (OR) = 15.74, 95% confidence interval (CI): 2.07-119.93, p = 0.008) and one year (OR = 3.18, 95% CI: 1.40-7.19, p = 0.006), respectively. The miR-126-3p to miR-223-3p ratio was related to a decreased risk of occurrence of EP within 30 days (OR = 0.14, 95% CI: 0.03-0.61, p = 0.009) and one year (OR = 0.37, 95% CI: 0.17-0.82, p = 0.014), respectively. MiRNAs were identified as independent predictors of EP even after adjustment for confounding clinical predictors. Adding miR-223-3p and miR-126-3p to miR-223-3p ratios as predictors into the model calculating the ischemic risk significantly increased the predictive accuracy for combined ischemic EP within one year more than using only clinical ischemic risk parameters. No associations between miRNAs and bleeding complications were identified. Conclusion. The miR-223-3p and the miR-126-3p are promising independent predictors of thrombotic events and can be used for ischemic risk stratification after AMI.

Citovat

HROMADKA, Milan, Zuzana MOTOVSKA, Ota HLINOMAZ, Petr KALA, Frantisek TOUSEK, Jiří JARKOVSKÝ, Markéta BERANOVÁ, Pavel JANSKY, Michal SVOBODA, Iveta KŘEPELKOVÁ, Richard ROKYTA, Petr WIDIMSKY and Michal KARPISEK. MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty. JOURNAL OF PERSONALIZED MEDICINE. BASEL: MDPI, 2021, vol. 11, No 6, p. 1-12. ISSN 2075-4426. Available from: https://dx.doi.org/10.3390/jpm11060508.

@article{1783535,
   author = {Hromadka, Milan and Motovska, Zuzana and Hlinomaz, Ota and Kala, Petr and Tousek, Frantisek and Jarkovský, Jiří and Beranová, Markéta and Jansky, Pavel and Svoboda, Michal and Křepelková, Iveta and Rokyta, Richard and Widimsky, Petr and Karpisek, Michal},
   article_location = {BASEL},
   article_number = {6},
   doi = {http://dx.doi.org/10.3390/jpm11060508},
   keywords = {acute myocardial infarction; risk stratification; microRNA; miR-126-3P; miR-223-3p; antithrombotic therapy individualization},
   language = {eng},
   issn = {2075-4426},
   journal = {JOURNAL OF PERSONALIZED MEDICINE},
   title = {MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty},
   url = {https://www.mdpi.com/2075-4426/11/6/508},
   volume = {11},
   year = {2021}
}

TY  - JOUR
ID  - 1783535
AU  - Hromadka, Milan - Motovska, Zuzana - Hlinomaz, Ota - Kala, Petr - Tousek, Frantisek - Jarkovský, Jiří - Beranová, Markéta - Jansky, Pavel - Svoboda, Michal - Křepelková, Iveta - Rokyta, Richard - Widimsky, Petr - Karpisek, Michal
PY  - 2021
TI  - MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty
JF  - JOURNAL OF PERSONALIZED MEDICINE
VL  - 11
IS  - 6
SP  - 1-12
EP  - 1-12
PB  - MDPI
SN  - 20754426
KW  - acute myocardial infarction
KW  - risk stratification
KW  - microRNA
KW  - miR-126-3P
KW  - miR-223-3p
KW  - antithrombotic therapy individualization
UR  - https://www.mdpi.com/2075-4426/11/6/508
N2  - Aim. This study was designed to evaluate the relationship between microRNAs (miRNAs), miR-126-3p and miR-223-3p, as new biomarkers of platelet activation, and predicting recurrent thrombotic events after acute myocardial infarction (AMI). Methods and Results. The analysis included 598 patients randomized in the PRAGUE-18 study (ticagrelor vs. prasugrel in AMI). The measurements of miRNAs were performed by using a novel miRNA immunoassay method. The association of miRNAs with the occurrence of the ischemic endpoint (EP) (cardiovascular death, nonfatal MI, or stroke) and bleeding were analyzed. The miR-223-3p level was significantly related to an increased risk of occurrence of the ischemic EP within 30 days (odds ratio (OR) = 15.74, 95% confidence interval (CI): 2.07-119.93, p = 0.008) and one year (OR = 3.18, 95% CI: 1.40-7.19, p = 0.006), respectively. The miR-126-3p to miR-223-3p ratio was related to a decreased risk of occurrence of EP within 30 days (OR = 0.14, 95% CI: 0.03-0.61, p = 0.009) and one year (OR = 0.37, 95% CI: 0.17-0.82, p = 0.014), respectively. MiRNAs were identified as independent predictors of EP even after adjustment for confounding clinical predictors. Adding miR-223-3p and miR-126-3p to miR-223-3p ratios as predictors into the model calculating the ischemic risk significantly increased the predictive accuracy for combined ischemic EP within one year more than using only clinical ischemic risk parameters. No associations between miRNAs and bleeding complications were identified. Conclusion. The miR-223-3p and the miR-126-3p are promising independent predictors of thrombotic events and can be used for ischemic risk stratification after AMI.
ER  -

HROMADKA, Milan, Zuzana MOTOVSKA, Ota HLINOMAZ, Petr KALA, Frantisek TOUSEK, Jiří JARKOVSKÝ, Markéta BERANOVÁ, Pavel JANSKY, Michal SVOBODA, Iveta KŘEPELKOVÁ, Richard ROKYTA, Petr WIDIMSKY and Michal KARPISEK. MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty. \textit{JOURNAL OF PERSONALIZED MEDICINE}. BASEL: MDPI, 2021, vol.~11, No~6, p.~1-12. ISSN~2075-4426. Available from: https://dx.doi.org/10.3390/jpm11060508.

Detailed Information on Publication Record